Chimerix, Inc. (NASDAQ:CMRX) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET

Company Participants

Will O’Connor - Stern Investor Relations
Mike Andriole - President and Chief Executive Officer
Michelle LaSpaluto - Chief Financial Officer
Josh Allen - Chief Technology Officer
Allen Melemed - Chief Medical Officer
Tom Riga - Chief Operating and Commercial Officer

Conference Call Participants

Maury Raycroft - Jefferies
Soumit Roy - Jones Research
Ed White - HC Wainwright
Troy Langford - TD Cowen

Operator

Good morning, ladies and gentlemen. And welcome to the Chimerix Second Quarter 2024 Earnings Conference Call. I would now like to introduce you to your host for today’s call, Will O’Connor of Stern Investor Relations. Please proceed.

Will O’Connor

Thank you, operator. Good morning, everyone, and welcome to the Chimerix second quarter 2024 financial and operating results conference call. This morning, we issued a press release related to our second quarter operating update. You can access the press release in our Investors section of the website.

With me on today’s call are President and Chief Executive Officer, Mike Andriole; Chief Financial Officer, Michelle LaSpaluto; and Chief Technology Officer, Josh Allen. We also have Allen Melemed, our Chief Medical Officer and Tom Riga, our Chief Operating and Commercial Officer for question.

Before we begin, I’d like to remind you that the statements made on today’s call will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties and other factors.

These risks and uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. Please refer to our filings with the SEC for a more complete disclosure of these risks and uncertainties.

At this time, I’ll now turn the call over to Chimerix’s President and Chief Executive Officer, Mike Andriole.

Mike Andriole

Thanks, Will. Good morning, everyone, and thank you for joining us. It's been a busy summer at Chimerix and we continue to make meaningful progress across our clinical programs. Starting with our lead program, dordaviprone, our team continues to be laser-focused on the execution and enrollment of the Phase 3 ACTION study, which is on track for the first interim overall survival readout in the third quarter of next year. We're executing with urgency as there remains a significant need for patients battling this lethal disease. With no approved treatment options available that have proven clinical benefit beyond radiation therapy, we're keenly aware of the importance of speed in addressing this unmet need.